Kornimate/medical-research-clean huggingface dataset:
nulliparous women and education and counseling

Conditions: Pregnancy

Summary: this study investigates the effect of education and counseling on anxiety and depression in nullipar women.

pregnancy is a special process in a woman's life in which physiological, social and psychological changes occur. in this process, most women experience anxiety and depression, which are an important global health problem.the fear of uncertainty experienced by women who will become mothers for the first time may cause them to experience more anxiety/depression. the aim of this study was to investigate the effect of education and counseling on anxiety and depression of women. this randomized controlled study was conducted at state hospital in northern turkey , obstetrics and gynecology polyclinic between january 2022 and march 2022. volunteer women undergoing polyclinic have been included. participants were randomly assigned to the intervention or the control group using a computer-generated list. a data collection form including socio-demographic and obstetric characteristics such as age, educational status, hospital anxiety depression scale (hads) was used for each patient. after obtaining written informed consent, the data collection form, hospital anxiety depression scale (hads) were applied to both groups by face to face interview. immediately after the questionnaires were applied, the nurse gave individual education and counseling were giving by the nurse researcher to intervention group for 30 minutes. participants in the control group received standard care (verbal information about procedure and a short written information about the procedure) and no intervention (education and counseling) was performed.the ibm spss (statistical package for the social sciences) 23.0 package program was used to evaluate the data obtained in the study.

Eligibility criteria:
inclusion criteria: * a healthy pregnant woman over 18 years of age, * without a diagnosed psychiatric disease, * without mental disability and communication problems, * at 28 weeks of gestation, * nulliparous, * without fetal anomaly, * without risky pregnancy exclusion criteria: * a healthy pregnant woman under 18 years of age, * with a diagnosed psychiatric disease, * with mental disability and communication problems, * under 28 weeks of gestation, * multiparous, * with fetal anomaly, * with risky pregnancy

Keywords: nulliparous momen
peng vs intra-articular injection for hip arthroscopy

Conditions: Opioid Use; Acute Pain

Summary: hip arthroscopy is a popular surgical method that is increasingly being used for both intraarticular and extraarticular hip surgeries. postoperative acute pain is difficult to control in hip surgeries due to the complex nature of hip innervation and the large number of surgical interventions. optimal treatment of postoperative pain in hip arthroscopy is very important to be able to perform rehabilitation, avoid opioid side effects and minimize unplanned re-hospitalization. regional anesthesia techniques are widely used because of their proven efficacy in post-surgical pain management and their safety profile that ultimately contributes to early recovery. many regional techniques such as neuraxial blocks, lumbar plexus block, femoral nerve block, fascia iliac block and intraarticular local anesthetic injection have been used for the treatment of acute postoperative pain. femoral nerve and fascia iliac blocks have shown good results for long-term post-surgery analgesia. however, the obturator nerve and accessory obturator nerve should be targeted to achieve more effective perioperative pain control. there are studies reporting that pericapsular nerve group block (peng), which has been defined in recent years, provides effective perioperative analgesia in hip surgeries. in this study, we aim to compare the effectiveness of peng block and intra-articular local anesthetic injection in hip arthroscopy.


Eligibility criteria:
inclusion criteria: * american association of anesthesiologists (asa) physical status i - iii * bmi 20 to 35 kg / m2 * patients scheduled for elective hip arthroscopy * able to provide informed consent. exclusion criteria: * patients who refuse to participate in the study, * coagulopathy, * sepsis, * hepatic or renal insufficiency, * pregnancy * allergy to local anesthetic drugs, * chronic pain condition requiring opioid intake at home, * bmi above 40. * history of psychiatric diseases needing treatment. * failure of nerve block * substance abuse history * hip revision surgery * underlying neurologic disorder affecting pain perception. * angina, heart attack, heart failure * kidney or hepatic insufficiency * stroke * gastrintestinal bleeding history

Keywords: hip arthroscopy, intra-articular injection, peng block
multiple ascending doses (mad) of anti-a disintegrin and metalloproteinase with thrombospondin motifs-5 (anti-adamts-5) nanobody in participants with knee osteoarthritis (oa)

Conditions: Osteoarthritis, Knee

Summary: the study will be conducted in participants with symptomatic knee oa to explore the safety, tolerability, immunogenicity, pharmacokinetics (pk), and pharmacodynamics (pd) of mad of m6495.


Eligibility criteria:
inclusion criteria: * kellgren lawrence (kl) radiological grade of 2 to 4 in the target knee * western ontario and mcmaster universities osteoarthritis index (womac) pain subscore of greater than or equal to (\>=) 40 out of 100 in the target knee at screening * primary or post-traumatic femorotibial oa according to american college of rheumatology clinical and radiographic criteria * have completed at least 4 days of the participant 7-day diary in the period from day -8 to day 1 * can give signed informed consent * other protocol defined inclusion criteria could apply exclusion criteria: * history of arthroscopy or intra-articular administration of corticosteroids or hyaluronic acid into the target knee within 6 months before screening * intention of having major knee surgeries or total knee replacement during the time frame of this study in either knee * secondary oa in target knee joint because of joint dysplasia, aseptic osteonecrosis, acromegaly, paget disease, stickler syndrome, hemochromatosis, gout, chondrocalcinosis, or calcium pyrophosphate deposition disease * any known active systemic infection, including infection that might compromise the immune system such as human immunodeficiency virus, or hepatitis b or c * history of myocardial infarction or cerebrovascular event within 6 months prior to screening, or current active angina pectoris, symptomatic heart failure, seizures, untreated hypertension, gastrointestinal bleeding, or any other significant medical condition in the investigator's opinion * history of cancer, except adequately treated basal cell or squamous cell carcinoma of the skin or carcinoma in situ/cervical intraepithelial neoplasia of the uterine cervix, unless considered cured \>= 5 years * other protocol defined exclusion criteria could apply

Keywords: m6495 anti-adamts-5 nanobody osteoarthritis
thulium contact laser of laryngotracheal stenosis

Conditions: Laryngeal Carcinoma; Bilateral Vocal Cord Paresis; Subglottic Stenosis

Summary: the purpose of the study is to compare results of the treatment of tumorous and non-tumorous laryngotracheal stenosis using thulium contact laser versus carbon dioxide laser used in the past.

laryngotracheal stenosis is a serious disease significantly worsening the quality of life. impaired breathing often leads to tracheotomy, deterioration of the voice leads to communication problems with others and swallowing problems are often present, as well the main causes of laryngotracheal stenosis are post intubation and post tracheostomy conditions, inflammatory process (often autoimmune), tumors (mainly squamous cell carcinoma and chondroma) and trauma. within the last years there is substantial shift in the treatment strategy from open surgery to endoscopic techniques. however, surgical treatment is often difficult due to demanding exposure of tumor and problematic margins control. in recent years there has been a development of particular techniques of endoscopic resection of tumors and non-malignant laryngeal glottic and subglottic stenosis using a carbon dioxide (co2) laser with promising improvement of treatment results. however, co2 laser has some limitations, particularly in the treatment of tumors spreading into anterior commissure, because co2 laser beam cannot get "around the corner". moreover, subglottic area is also difficult to be reached by co2 laser beam. therefore, contact laser with adjustable manipulators with possibility to bend tip of manipulator according to the actual need seems to be of some advantage.

Eligibility criteria:
inclusion criteria: 1. patients with t1-t2 (some t3) laryngeal carcinoma 2. patients with bilateral vocal cord paralysis treated with partial arytenoidectomy and laterofixation 3. patients with subglottic stenosis treated endoscopically exclusion criteria: * non signing of informed consent

Keywords: laryngeal carcinoma bilateral vocal cord paralysis laryngotracheal stenosis laser treatment decannulation voice swallowing
inhaled albuterol sulfate for acute wheezing due to obstructive airways disease in children

Conditions: Asthma

Summary: this study evaluates the effect of cumulative dose administration of albuterol sulfate inhalation aerosol delivered with valved holding chamber and facemask. this is a four week study in birth to 23 month old subjects who are experiencing acute wheezing due to obstructive airways disease.


Eligibility criteria:
inclusion criteria: * must be an outpatient. * age at second visit must be birth to \<24 months old. * parent/guardian who is willing to sign, or has signed, an informed consent. * must have acute wheezing consistent with reversible obstructive airway disease. * must have an asthma symptoms score between 4-9 based on the tal score (modified tal asthma symptoms score measured by the study site) at screening (visit 1) while the subject is breathing room air. exclusion criteria: * history of life-threatening asthma or wheezing that requires admission to an intensive care unit for treatment within 3 months prior to screening, or he/she has been treated in the emergency room and admitted to the hospital for airways obstruction on two or more occasions within 3 months prior to screening, or there is a history of intubation for respiratory distress due to airways obstruction. * has impending respiratory failure. * taken medications such as acute/chronic systemic corticosteroids, cns stimulants, investigational medications, theophylline or aminophylline, anti-arrhythmic within a certain time period prior to the study. * having the following signs or symptoms: 1)present with fever (rectal temperature \>100.5 ºf or tympanic temperature \>101.5ºf); 2) present with known pulmonary (lung) and/or cardiac (heart) congenital malformations; 3) have an underlying chronic disease (respiratory (chronic pulmonary disease includes congenital anomalies, bronchopulmonary dysplasia, and cystic fibrosis), cardiac, renal, or liver insufficiency, immunodeficiency, encephalopathy); 4) known or suspected foreign body aspiration; 5) their modified tal asthma symptoms score is 10; 6) their weight is below a certain limit for the average for their age; 8) they were born before 34 weeks' gestation. 9) laboratory tests for serum potassium and blood glucose within the following limits (potassium between 3.0-5.8 meq/l and glucose between 45-140mg/dl).

Keywords: wheezing bronchospasm albuterol sulfate hfa
telehealth-based symptom management for veterans treated with selinexor

Conditions: Multiple Myeloma; Large-cell Lymphoma

Summary: the purpose of this study is to find out if continued monitoring of side effects from selinexor and prescribed medication to prevent side effects helps improve symptoms, quality of life, and ability to continue the treatment longer.

the primary objective of this study is to evaluate control of treatment-related and cancer-associated symptoms over the first three months of therapy with selinexor in veterans who participate in a telehealth symptom management intervention. the secondary objectives are: * to describe characteristics of patients treated with selinexor. * to describe adherence with the telehealth intervention. * to define the type and frequency of adverse events that patients experience while taking selinexor. * to describe the duration of selinexor therapy and evaluate adherence and dose intensity of selinexor in va cancer patients receiving a telehealth symptom management intervention. * to describe concomitant medication usage in patients treated with selinexor. * to assess quality of life in patients treated with selinexor in the va. * to estimate progression-free survival in va cancer patients treated with selinexor.

Eligibility criteria:
inclusion criteria: * diagnosis of b-cell malignancy: either relapsed or refractory multiple myeloma or diffuse large b-cell lymphoma, meeting the fda-approved indication for selinexor treatment. * requiring therapy as assessed by the treating oncology provider. * prior authorization drug request for selinexor approved by va oncology pharmacist. * subject age 18 years or older. * subject willing and able to perform video or telephone research visits. * subjects must be able to read and comprehend english. * subject must be a veteran receiving cancer care from a va facility affiliated with the national teleoncology program. * patients must be enrolled prior to starting selinexor. exclusion criteria: * any prior or current therapy with selinexor. * any medical, psychiatric, or cognitive issue that the principal investigator or the subject's oncologists believes would prevent participation or completion of the study. * individuals who are vulnerable to coercion or undue influence. * any individuals or populations that may temporarily or permanently require additional considerations include such as those susceptible to coercion or undue influence (e.g., patients with limited or no treatment options, socially and economically disadvantaged persons). * current selinexor therapy that is part of an investigational clinical trial.
effects of levosimendan, milrinone and norepinephrine on left and right ventricular function in septic shock

Conditions: Septic Shock; Cardiomyopathy

Summary: the aim of this study is to investigate the effects milrinon and levosimandan on n heart function in septic cardiomyopathy and how norepinephrine affects the left and right ventricular function in patients with septick shock using pulmonary artery catheter, conventional and strain echocardiography.

this is a prospective study where 30 patients with septic chock during the care in icu, will be included. patients with a history of previous heart disease are excluded from the study. each patient is in need of norepinephrine infusion and on mechanical ventilation. initially the mean arterial pressure (map) is randomly changed from 60 to 75 and then to 90 mmhg. hemodynamic variables as blood pressure, cardiac output, pulmonary artery occlusion pressure (paop) will be registerd at each map-level, arterial line and pulmonary artery catheter (pac) and the cardiac function will be assessed with conventional and strain echocardiography. then, if the echocardiogram shows impaired lv-function will the patient be randomized to receive either milrinone or levosimendan. hemodynamic variables as blood pressure, cardiac output, pulmonary artery occlusion pressure (paop) will be registered again, as well the cardiac function with conventional and strain echocardiography. echocardiograms will be analysed for the determination of lv an rv strain. potential differences between different levels of blood pressure as well as effects of milrinone or levosimendan on hemodynamic and echocardiographyc variables will be analysed.

Eligibility criteria:
inclusion criteria: * septic shock. * all patients will be resuscitated with fluids before the inclusion. * need of norepinephrine infusion. * myocardial dysfunction in echocardiogram, either lvef \< 50% or global left ventricular systolic strain over -15%. exclusion criteria: * history of previous heart disease or pulmonary hypertension. * age \< 18 years. * cardiac arrhythmia.

Keywords: levosimendan milrinone myocardial strain septic cardiomyopathy norepinephrine
kangaroo mother care to prevent hypothermia in preterm infants

Conditions: Hypothermia, Newborn

Summary: the overall hypothesis is that better adherence to kangaroo mother care (kmc) in combination with existing who thermoregulation care will reduce the incidence of moderate hypothermia (32-36 degrees c) or severe hypothermia (\<32.0 degrees c) in preterm infants (32-36 6/7 weeks of gestational age) when compared with routine who thermoregulation alone.

the overall hypothesis is that better adherence to kangaroo mother care (kmc) in combination with existing world health organization (who) thermoregulation care (warm delivery rooms, immediate drying after birth, kmc whenever possible, early and exclusive breastfeeding, postponement of bathing and weighing, appropriate bundling, and use of air incubator, radiant warmer, or heat mattress if the neonate develops hypothermia) will reduce the incidence of moderate hypothermia (32-36 degrees c) or severe hypothermia (\<32.0 degrees c) in preterm infants (32-36 6/7 weeks of gestational age) when compared with routine who thermoregulation alone.

Eligibility criteria:
inclusion criteria: * estimated gestational age 32-36 6/7 weeks * delivery in the hospital exclusion criteria: * abdominal wall defect or myelomeningocele * major congenital anomalies * blistering skin disorder

Keywords: hypothermia newborn hyperthermia kangaroo mother care
prognostic performance of the naples prognostic score

Conditions: Nutritional and Metabolic Diseases; Oncologic Disorders

Summary: to investigate the prognostic performance of the naples prognostic score in gastric cancer patients undergoing surgery

the outcome of oncological patients is related not only to the tumor status but also to the host. particularly the patient's immune and nutritional status have been recently associated with short- and long-term outcome in gastric and other cancers. in addition, there is growing evidence that systemic inflammation plays a crucial role in the carcinogenesis and progression of gastric cancer. the neutrophil to lymphocyte ratio (nlr), and, more recently, the lymphocyte to monocyte ratio (lmr) have been shown to be independently correlated with prognosis in patients with gastric cancer who underwent surgery, and preoperative albumin and cholesterol levels seem to be adequate mirrors of the nutritional status of the host. the investigators have already demonstrated that a new scoring system, which they called naples prognostic score (nps), based on a composite score of albumin and cholesterol concentrations, along with nlr and lmr is a simple tool strongly associated with long-term outcome in patients undergoing surgery for colorectal cancer. the aim of this study is to assess the correlation between the nps and clinicopathological characteristics, postoperative complication rate and long-term outcome in patients undergoing surgery for gastric cancer. furthermore, the new prognostic scoring system will be compared with previously developed ones and the current tnm staging system to evaluate its performance. all patients who underwent surgery for proven gastric adenocarcinoma at the division of surgical oncology of the gastrointestinal tract of the university of campania (naples, italy), from january 2000 to december 2015 will be enrolled in the present study.

Eligibility criteria:
inclusion criteria: * all patients undergoing surgery at our institution for proven gastric adenocarcinoma will be enrolled in the present study exclusion criteria: * patients with lower esophageal adenocarcinoma or cancer crossing the esophagogastric junction with its epicenter in the proximal 2 cm of stomach, which were taken apart from stomach cancers in the last two ajcc cancer staging editions, will be excluded. * patients with ongoing infections, concomitant immune-mediated diseases, or on drugs capable of affecting neutrophil and/or lymphocyte counts (e.g., steroids, immunosuppressants, etc.) will be excluded from the study.

Keywords: gastric cancer
developing a lifestyle intervention for south asians

Conditions: Behavior, Health; Pre Diabetes; Diabetes

Summary: this study aims to test the hypothesis that a culturally tailored lifestyle intervention can improve health behaviors among south asians with prediabetes and diabetes

this pre-post pilot study is a 16 week lifestyle program for south asians with prediabetes or diabetes in atlanta. patients will participate in physician-led group visits every other week focused on improving dietary and exercise practices to reduce weight.

Eligibility criteria:
inclusion criteria: 1. age \> 18 years; 2. confirmed diagnosis of prediabetes or t2d (documented a1c of ≥ 5.7%, 2-hour post-load glucose of \>140, or fbg of \>100); 3. a family member or peer willing to participate and attend all sessions as a social influencer; 4. proficiency in english of at least one member of each dyad, 5. willingness to provide written consent. exclusion criteria: 1. type 1 diabetes or diabetes secondary to other conditions (e.g. steroid-induced, pancreatic insufficiency, or chemotherapy-induced); 2. malignancy or life-threatening illness with life expectancy of \<5 years; 3. end-stage disease or serious illness that prohibits participation (e.g. end-stage renal disease or class iv congestive heart failure); 4. inability to perform unsupervised physical activity; 5. pregnancy; 6. diagnosed cognitive deficits or limited decision-making capacity; 7. alcohol or substance abuse; 8. homelessness or no fixed address.

Keywords: south asian adults patient-centered approach intensive lifestyle interventions diabetes
jab-30355 in patients with advanced solid tumors harboring tp53 y220c mutation

Conditions: Solid Tumors

Summary: this study is to evaluate the efficacy and safety of jab-30355 in adult participants with advanced solid tumors harboring tp53 y220c mutation.

this study consists of two parts: dose escalation phase (phase 1) and dose expansion phase (phase 2a). the primary objective of dose escalation is to evaluate the safety and tolerability, and to determine the mtd of jab-30355 monotherapy administered in participants with advanced solid tumors harboring tp53 y220c mutation. dose expansion will further explore jab-30355's clinical benefit and tolerability in selected dose levels.

Eligibility criteria:
inclusion criteria: * written informed consent. * participant must be ≥18 years of age at the time of signing the informed consent form (icf). * ecog performance status score of 0 or 1. * has been treated with at least one line of systemic therapy for that tumor type and stage. * have documentation of confirmed tp53 y220c mutation. * at least 1 measurable lesion per recist v1.1. * adequate hematological, renal and hepatic function and appropriate coagulation condition. * able to swallow and retain orally administered medication. exclusion criteria: * active brain or spinal metastases or primary cns tumor. * active infection requiring systemic treatment within 7 days. * active hbv or hcv. * any severe and/or uncontrolled medical conditions. * lvef ≤50% assessed by echo or muga. * qtcf\>470 msec.